Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$34.42−1.49 (-4.15%)
Close on Nov 18, 2026Market cap $1.18BP/E –Yield –
Nektar Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Nektar Therapeutics's operating cash flow for the twelve months ending Dec 31, 2025 was -$208.51M. For fiscal 2025 it was -$208.51M. The highest annual figure on record is $718.21M in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$208.51M | – |
| FY2024 | Dec 31, 2024 | -$175.71M | – |
| FY2023 | Dec 31, 2023 | -$192.61M | – |
| FY2022 | Dec 31, 2022 | -$304.01M | – |
| FY2021 | Dec 31, 2021 | -$412.66M | – |
| FY2020 | Dec 31, 2020 | -$313.29M | – |
| FY2019 | Dec 31, 2019 | -$328.68M | -145.8% |
| FY2018 | Dec 31, 2018 | $718.21M | – |
| FY2017 | Dec 31, 2017 | -$80.41M | – |
| FY2016 | Dec 31, 2016 | -$117.02M | – |
| FY2015 | Dec 31, 2015 | -$73.08M | – |
| FY2014 | Dec 31, 2014 | -$142.01M | – |
| FY2013 | Dec 31, 2013 | -$38.53M | – |
| FY2012 | Dec 31, 2012 | -$129.76M | – |
| FY2011 | Dec 31, 2011 | -$113.74M | – |
| FY2010 | Dec 31, 2010 | -$55.87M | -240.6% |
| FY2009 | Dec 31, 2009 | $39.74M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$64.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$48.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.74M | – |
| Q1 FY2025 | Mar 31, 2025 | -$49.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$43.93M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$47.89M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.05M | – |
| Q3 FY2023 | Sep 30, 2023 | -$42.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$51.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.70M | – |
| Q3 FY2022 | Sep 30, 2022 | -$82.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$74.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$88.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$151.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$101.14M | – |
| Q2 FY2021 | Jun 30, 2021 | -$82.90M | – |
| Q1 FY2021 | Mar 31, 2021 | -$77.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$98.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$52.68M | – |
| Q2 FY2020 | Jun 30, 2020 | -$83.90M | – |
| Q1 FY2020 | Mar 31, 2020 | -$78.08M | – |
| Q4 FY2019 | Dec 31, 2019 | -$125.22M | – |
| Q3 FY2019 | Sep 30, 2019 | -$68.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$53.92M | -105.6% |
| Q1 FY2019 | Mar 31, 2019 | -$80.90M | – |
| Q4 FY2018 | Dec 31, 2018 | -$117.55M | – |
| Q3 FY2018 | Sep 30, 2018 | -$71.41M | -176.7% |
| Q2 FY2018 | Jun 30, 2018 | $959.64M | – |
| Q1 FY2018 | Mar 31, 2018 | -$52.47M | – |
| Q4 FY2017 | Dec 31, 2017 | -$80.40M | – |
| Q3 FY2017 | Sep 30, 2017 | $93.08M | – |
| Q2 FY2017 | Jun 30, 2017 | -$58.52M | – |
| Q1 FY2017 | Mar 31, 2017 | -$34.57M | – |
| Q4 FY2016 | Dec 31, 2016 | -$52.41M | – |
| Q3 FY2016 | Sep 30, 2016 | -$27.36M | – |
| Q2 FY2016 | Jun 30, 2016 | -$13.60M | – |
See a number that looks wrong?